Feline Hemangiosarcoma Study Guide

Overview and Clinical Importance

Hemangiosarcoma (HSA) is a highly malignant neoplasm arising from vascular endothelial cells. While common in dogs, HSA is relatively rare in cats, occurring in approximately 0.5% of feline neoplasms. However, when it does occur, it carries significant clinical importance due to its aggressive behavior, high metastatic potential, and often poor prognosis. Understanding feline HSA is essential for the NAVLE as it represents a critical differential diagnosis for cats presenting with acute collapse, hemoabdomen, or cutaneous masses.

Unlike canine HSA where splenic involvement predominates, feline HSA shows a different distribution pattern with cutaneous and subcutaneous forms being more commonly diagnosed, likely due to their visible nature. Visceral forms in cats most frequently affect the liver, followed by the spleen, intestines, and abdominal lymph nodes. Recognition of species-specific differences is crucial for appropriate clinical management.

Etiology and Pathophysiology

Cell of Origin

Hemangiosarcoma originates from vascular endothelial cells or their precursors (hemangioblasts). These are the cells that line the interior surface of blood vessels throughout the body. Because blood vessels are present in virtually every tissue, HSA can theoretically arise at any anatomic location.

Risk Factors

Anatomic Classification and Distribution

Feline HSA can be classified into four main types based on anatomic location, each with distinct clinical behavior and prognosis:

Clinical Presentation

Cutaneous and Subcutaneous HSA

Appearance: Red, purple, blue, or black raised nodules or plaques. Lesions may appear as solitary or multiple masses. Dermal tumors are often associated with solar-induced skin changes in surrounding tissue.

Common Locations: Pinnae (ears), eyelids, conjunctiva, nose, scalp, muzzle; less commonly ventral abdomen, flank, and groin.

Clinical Signs: Often incidental finding; may present with bleeding, ulceration, or cosmetic concern. Subcutaneous tumors may feel firm to soft beneath normal-appearing skin.

Visceral HSA

C - Collapse (acute)

O - Origin: vascular endothelium

L - Liver most common visceral site in cats

L - Light-colored cats at risk (cutaneous)

A - Anemia (82% of cats)

P - Pale gums/mucous membranes

S - Survival poor for visceral forms

E - Emergency: tumor rupture causes hemoabdomen

Diagnostic Approach

Laboratory Findings

Diagnostic Imaging

Abdominal Radiographs: May reveal abdominal mass, organomegaly, loss of serosal detail (suggesting effusion), hepatomegaly or splenomegaly. Limited sensitivity for detecting small masses or when significant effusion is present.

Abdominal Ultrasound: Modality of choice for visceral HSA. Can identify masses in spleen, liver, and other organs. HSA typically appears as heterogeneous, mixed echogenicity masses, often with cavitary (blood-filled) regions. Can detect free abdominal fluid and guide abdominocentesis. Importantly, ultrasound identifies only 33% of multifocal lesions - surgery often reveals more extensive disease.

Thoracic Radiographs: Essential for staging; 33% of cats with visceral HSA have pulmonary metastases at diagnosis. Look for nodular interstitial pattern or multiple pulmonary nodules.

Echocardiography: Important to assess for cardiac involvement, particularly right atrial masses (though less common in cats than dogs). Can detect pericardial effusion.

Cytology and Histopathology

Fine Needle Aspiration (FNA): Often non-diagnostic due to the highly vascular, blood-filled nature of HSA. Samples typically yield predominantly blood with low cellularity. FNA carries risk of hemorrhage from vascular tumors. NOT recommended for definitive diagnosis of suspected HSA.

Histopathology: Gold standard for diagnosis. Biopsy or surgical excision required. Characteristic features include irregular vascular channels lined by atypical endothelial cells, marked anisocytosis and anisokaryosis, mitotic figures, areas of hemorrhage and necrosis. Poorly differentiated tumors may form solid sheets without obvious vascular channels.

Abdominal Fluid Analysis: Hemorrhagic effusion consistent with hemoabdomen. PCV of fluid similar to or slightly lower than peripheral blood. Important to rule out other causes of hemoabdomen.

Immunohistochemistry (IHC)

IHC is essential for confirming diagnosis in poorly differentiated tumors and differentiating HSA from other spindle cell sarcomas.

Staging

Complete staging is essential for prognosis and treatment planning. Minimum database should include:

• Complete blood count with blood smear evaluation
• Serum chemistry panel
• Coagulation panel (PT, PTT, fibrinogen, D-dimers)
• Three-view thoracic radiographs
• Abdominal ultrasound
• Echocardiogram (especially if cardiac involvement suspected)

Treatment

Emergency Stabilization

For cats presenting with acute hemorrhage/collapse:

• IV fluid resuscitation (crystalloids, colloids)
• Blood transfusion if PCV less than 15-20%
• Oxygen supplementation
• Abdominal bandaging for tamponade effect
• Pericardiocentesis if pericardial effusion causing tamponade

Surgical Management

Chemotherapy

Unlike canine HSA, there is NO standard-of-care chemotherapy protocol for feline HSA. Limited data exists on chemotherapy efficacy in cats. Options extrapolated from canine protocols include:

Other Treatment Modalities

Radiation Therapy: May be used for local control when complete surgical excision is not possible. Limited data in cats.

Yunnan Baiyao: Chinese herbal medicine that may help control bleeding episodes. Mechanism unknown; used as palliative/supportive measure.

Prognosis

Feline vs Canine HSA: Key Comparisons